Tampa General Hospital Hematology and Medical Oncology

Topics

• Acute Myeloid Leukemia Research 423
• CAR-T cell therapy research 311
• Hematopoietic Stem Cell Transplantation 180
• Multiple Myeloma Research and Treatments 146
• Lymphoma Diagnosis and Treatment 112
• Myeloproliferative Neoplasms: Diagnosis and Treatment 107
• Chronic Lymphocytic Leukemia Research 74
• Cancer Immunotherapy and Biomarkers 73
• Acute Lymphoblastic Leukemia research 48
• Genital Health and Disease 46
• Renal cell carcinoma treatment 36
• Immunotherapy and Immune Responses 34

Most cited

1. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.

   The New England journal of medicine · 2022 · 1,350 citations · Frederick Locke

2. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.

   Nature · 2023 · 458 citations · Manish Patel

3. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.

   Lancet (London, England) · 2021 · 704 citations · Bijal Shah

4. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.

   Blood · 2023 · 409 citations · Frederick Locke

5. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

   Blood · 2025 · 135 citations · Shonali Midha, Frederick Locke

6. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.

   The New England journal of medicine · 2023 · 409 citations · Frederick Locke